Brief: Clarity Pharmaceuticals Posts HY Loss From Ordinary Activities After Tax A$23.582 Million
28/02/2025 04:58
Feb 28 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX: HY LOSS FROM ORDINARY ACTIVITIES AFTER TAX A$23.582 MILLION Further company coverage: CU6.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial